Int. Day of Action for Women’s Health

May 28, 2022

May 28th has been commemorated by women ’s health advocates and their communities since 1987, when during the International Women’s Health Meeting in Costa Rica, Latin American and Caribbean Women’s Health Network (LACWHN) proposed to celebrate May 28 annually as the International Day of Action for Women’s Health

Today, May 28th is a Day of Action recognized internationally wherein any organisation or individual can mobilise their communities around their own priority topic best suiting the local context. Any organisation working to advance women’s health rights is welcome to launch May 28th activities, in the aim of ensuring women’s health and well-being worldwide.

On this occasion, FH Europe partners with Erasmus University Medical Center and the Dutch expertise centre FH – Stichting LEEFH from the Netherlands,  University of Oslo, Department of Nutrition, National Advisory Unit on FH (NKTforFH),  Oslo University Hospital, from Norway,  to launch officially an international survey on women and FH. The aim is to better understand how familial hypercholesterolemia (FH for short) affects women, their family planning decisions as well as health pre-, during and post pregnancy. The response goal is ambitious. “Together we hope to reach 1000 women globally. It is the first of its kind project initiated in collaboration between research centres in Norway, the Netherlands and our Network. To date no other research about women living with FH has been carried out at this scale. The collected data will help us improve lives of many women and their families living with inherited high cholesterol.” says Magdalena Daccord, Chief Executive of FH Europe.

Read the official statement [PDF] and join the survey

FH Europe is registered as a charity; Charity number 1170731, registered in England and Wales.

FH Europe is registered as a charity; Charity number 1170731, registered in England and Wales.

FH Europe is supported by an educational grant from Amgen Limited, Sanofi, Regeneron, Akcea Therapeutics Inc. and Amryt
Site by: Vovi Web Design